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ARTICLE
Proximal microdeletions and microduplications of
1q21.1 contribute to variable abnormal phenotypes
Jill A Rosenfeld1, Ryan N Traylor1, G Bradley Schaefer2, Elizabeth W McPherson3, Blake C Ballif1,
Eva Klopocki4, Stefan Mundlos4, Lisa G Shaffer*,1 and Arthur S Aylsworth5, 1q21.1 Study Group6
Chromosomal band 1q21.1 can be divided into two distinct regions, proximal and distal, based on segmental duplications
that mediate recurrent rearrangements. Microdeletions and microduplications of the distal region within 1q21.1, which are
susceptibility factors for a variety of neurodevelopmental phenotypes, have been more extensively studied than proximal
microdeletions and microduplications. Proximal microdeletions are known as a susceptibility factor for thrombocytopenia-absent
radius (TAR) syndrome, but it is unclear if these proximal microdeletions have other phenotypic consequences. Therefore, to
elucidate the clinical significance of rearrangements of the proximal 1q21.1 region, we evaluated the phenotypes in patients
identified with 1q21.1 rearrangements after referral for clinical microarray testing. We report clinical information for 55
probands with copy number variations (CNVs) involving proximal 1q21.1: 22 microdeletions and 20 reciprocal microduplications
limited to proximal 1q21.1 and 13 microdeletions that include both the proximal and distal regions. Six individuals with
proximal microdeletions have TAR syndrome. Three individuals with proximal microdeletions and two individuals with larger
microdeletions of proximal and distal 1q21.1 have a ‘partial’ TAR phenotype. Furthermore, one subject with TAR syndrome
has a smaller, atypical deletion, narrowing the critical deletion region for the syndrome. Otherwise, phenotypic features
varied among individuals with these microdeletions and microduplications. The recurrent, proximal 1q21.1 microduplications
are enriched in our population undergoing genetic testing compared with control populations. Therefore, CNVs in proximal
1q21.1 can be a contributing factor for the development of abnormal phenotypes in some carriers.
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INTRODUCTION
Chromosomal region 1q21.1 is structurally complex with many
segmental duplications (SDs) that make it prone to non-allelic
homologous recombination (NAHR).1 The 1q21.1 region contains
multiple sequence gaps based on the UCSC March 2006 build (hg18);
of the B5.6 Mb of sequence comprising 1q21.1, only 25% is com-
posed of unique sequence.2 Band 1q21.1 can be divided into two
distinct regions based on SD-mediated recurrent microdeletions/
microduplications: a proximal and a distal region (Figure 1). The
proximal region extends from B144.1 to B144.5 Mb from the 1p
telomere, contains 16 genes in its unique sequence, and is flanked by
SDs that mediate recurrent breakpoints (BPs) BP2 and BP3. The distal
region is located at B145 to B146.35 Mb, contains 13 genes, and is
flanked by SDs that mediate BP3 and BP4.2
Current literature demonstrates the phenotypic variability asso-
ciated with copy number variations (CNVs) in chromosome band
1q21.1. Microdeletions and microduplications of the distal 1q21.1
region have been linked with a variety of morbidities, including
intellectual disability (ID),2–6 autism,2,6–9 schizophrenia,10–16 micro-
cephaly/macrocephaly,2,6 congenital heart defects,17–20 and renal and
urinary tract anomalies21 (Supplementary Table 1). Proximal 1q21.1
microdeletions are hypothesized to be a prerequisite for thrombo-
cytopenia-absent radius (TAR) syndrome,22 but otherwise proximal
microdeletions and microduplications have been rarely reported,
in cohorts of individuals with Mayer–Rokitansky–Küster–Hauser
syndrome,23 congenital heart defects,24 and autism25 (Supplementary
Table 1). Both proximal and distal CNVs of 1q21.1 are reported
in phenotypically affected individuals and apparently normal
carriers.2,6,22 Although microdeletions and microduplications of distal
1q21.1 have been shown to be enriched in populations with abnormal
phenotypes,2,13,17 some conflicting data exists in case-control compar-
isons for proximal 1q21.1 CNVs,26,27 and it remains unclear if these
proximal CNVs have phenotypic consequences other than TAR
syndrome. Therefore, to clarify the clinical significance of rearrange-
ments of the proximal 1q21.1 region, we performed molecular and
clinical characterization of 55 probands with microdeletions or
microduplications encompassing the proximal 1q21.1 region in a
patient population undergoing clinical microarray-based comparative
genomic hybridization (aCGH) testing and compared the frequencies
of these rearrangements with reported control groups.
MATERIALS AND METHODS
Subject ascertainment
Individuals with 1q21.1 CNVs reported here were identified after referral for
molecular cytogenetic testing to clinical laboratories, including Signature
Genomics, University of Nebraska, Nationwide Children’s Hospital, Emory
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Genetics Laboratory, GeneDx, Hospital for Sick Children, and University of
North Carolina. Common indications for study included developmental delay
(DD), ID, dysmorphic features, and congenital anomalies. To compare the
phenotypes resulting from rearrangements of the proximal and/or distal
regions of 1q21.1, we included 18 subjects with deletions limited to distal
1q21.1, in addition to 55 subjects with proximal 1q21.1 rearrangements, in the
clinical analysis. Informed consent was provided for the publication of
photographs.
Molecular cytogenetic testing
Microdeletions and microduplications were identified at Signature Genomics
using bacterial artificial chromosome (BAC)-based microarrays or oligo-
nucleotide-based microarrays. Versions 1–4 of the BAC-based SignatureChip
(Signature Genomics, Spokane, WA, USA) only covered proximal 1q21.1,
whereas all other BAC-based and oligo-based arrays covered the whole genome
and, therefore, covered proximal and distal 1q21.1. Available samples tested on
versions 1–4 of the BAC arrays and found to have proximal 1q21.1 rearrange-
ments were reanalyzed using arrays that covered the proximal and distal
regions on 1q21.1. Reanalysis was performed with either a BAC-based
array (SignatureChipWG, Signature Genomics) or an oligo-based array
(SignatureChipOS versions 1 (105K-feature, Agilent Technologies, Santa Clara,
CA, USA) or 2 (135K-feature, Roche NimbleGen, Madison, WI, USA), both
custom designed by Signature Genomics), according to previously described
methods.28–31 Some samples were analyzed at other laboratories either by BAC
array (SignatureSelect v1.0 (Signature Genomics; subject 13) or Spectral Chip
2600 (PerkinElmer, Waltham, MA, USA; subject 67)), oligonucleotide array
(Agilent 44K-feature custom array (Agilent Technologies; subjects 10, 28–31,









































Figure 1 (a) Genomic architecture of 1q21.1 and representative aCGH results showing microdeletions and microduplications. At the top of the figure is a
partial ideogram showing chromosome band 1q21.1 with genomic coordinates corresponding to the hg18 build of the human genome. Orange bars represent
clusters of SD blocks BP1, BP2, BP3, and BP42 that contain the BPs of the recurrent rearrangements. Plots show the representative recurrent 1q21.1
microdeletions (blue shading) and microduplications (pink shading) found in subjects reported here. Values along the y axis represent log2 ratios of
patient:control signal intensities. The first three plots showing deletions are from a 105K-feature oligonucleotide microarray (SignatureChipOS, version 1),
and the plot showing the duplication is from a 135K-feature oligonucleotide microarray (SignatureChipOS, version 2). Black boxes represent sequence gaps
in the hg18 human genome build, and red boxes represent all known genes annotated in the Reference Sequence database in 1q21.1, except genes
between BP2 and BP3. *The HYDIN paralog is localized within the distal sequence gap in BP3.6 (b) Zoomed-in view of the BP2–BP3 interval and aCGH
results from subject 18, who had an atypical, small deletion within the proximal 1q21.1 region and clinically diagnosed TAR syndrome (chr1:144215938–
144 320 529). His deletion minimally extends from RBM8A to POLR3C and may extend proximally into LIX1L and distally into RNF115. Red boxes
represent all known genes annotated in the Reference Sequence database in the region.
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Laboratory, Decatur, Georgia; subject 9), or 105K-feature GenomeDx (GeneDx,
Gaithersburg, MD, USA), subjects 27, 34)), or single nucleotide polymorphism
(SNP) array (Genome-wide Human SNP Array 6.0 (Affymetrix, Santa Clara,
CA, USA; subject 12)).
Fluorescence in situ hybridization (FISH)
All abnormal microarray results obtained at Signature Genomics were visua-
lized by metaphase or interphase FISH using one or more BAC clones located
within the abnormal regions.33,34
RESULTS
We identified 55 probands with abnormalities involving the proximal
region of 1q21.1 (Figure 2). Of this group, 22 subjects (#1–22) had the
smaller proximal microdeletion flanked by BP2 and BP3, and 20
subjects (#36–55) had the reciprocal microduplication. The remaining
13 subjects (#23–35) had a larger microdeletion flanked by BP1 or BP2
and BP4 involving the proximal and distal regions (Figure 1). Also,
clinical information was available for 18 subjects (#56–73) with distal
microdeletions flanked by BP3 and BP4 (Supplementary Tables 3
and 4). Subject 19 had a complex rearrangement with a distal,
BP3–BP4 duplication as well as the proximal deletion. Subject 53
had a complex rearrangement with a proximal, BP2–BP3 duplication
and a duplication of the distal portion of the distal region, with
normal copy number intervening sequence. Subjects 20–22, 35, 54–55,
and 71–73 had additional clinically significant abnormalities found by
aCGH and were excluded from phenotypic analysis (Supplementary
Table 4). After these exclusions, clinical information for the remaining
49 probands with abnormalities involving proximal 1q21.1 is pre-
sented in Supplementary Table 2, and comparisons of clinical features
among individuals with 1q21.1 deletions and duplications are shown
in Tables 1 and 2, respectively.
Four of the probands with deletions limited to the proximal 1q21.1
region had clinically diagnosed TAR syndrome, and two additional
prenatal cases had skeletal findings consistent with TAR syndrome.
One of these probands, subject 18, had an atypical partial deletion of
the proximal 1q21.1 region (chr1:144 215 938–144 320 529, UCSC hg18
coordinates; Figure 1). The phenotypic features of TAR syndrome and
other individuals with proximal 1q21.1 microdeletions not meeting
full clinical criteria for TAR syndrome are summarized in Table 3.
Among the 55 probands with proximal 1q21.1 abnormalities,
inheritance was known for 22 deletions and 7 duplications. Micro-
deletions flanked by BP2 and BP3 were apparently de novo in
6 subjects and inherited in 11 subjects, including 1 from a mildly
affected father and at least 4 from apparently normal mothers.
Pedigrees of selected families with proximal deletions are shown in
Figure 3. Microdeletions flanked by BP1/2 and BP4 were apparently
de novo in four subjects and inherited in one, from a mildly affected
father. Microduplications flanked by BP2 and BP3 were inherited in
seven subjects, including one from a mother with mild learning delays
and short stature, one from a father with learning disabilities and cleft
lip, and at least one from an apparently normal parent.
To enable a frequency comparison of individuals with proximal
1q21.1 abnormalities in ‘normal’ and ‘abnormal’ populations, data
from 45744 probands undergoing aCGH testing at Signature Geno-
mics were analyzed. Analysis for distal 1q21.1 was limited to 30215
probands tested on arrays with coverage of the distal 1q21.1 region
(Table 4). The frequency of microduplications limited to the proximal,
BP2–BP3 segment of 1q21.1 in our patient population who underwent
aCGH testing compared with a sum of control individuals reported in
the literature (Supplementary Table 1) showed an enrichment in our
patient population (72/45744 vs 9/11057; one-tailed P¼0.033, Fisher’s
exact test). The microdeletions limited to the proximal, BP2–BP3
Figure 2 (a, b) Subject 6 (with proximal microdeletion) at 20 months. Note slight epicanthal folds, mild left ptosis, broad nasal root with round tip, and
normal ears. (c–e) Subject 13 (with proximal microdeletion and clinically diagnosed TAR syndrome) at 17 months. Note shortened forearms and adducted
thumb. (f) Radiograph of subject 13, who had radial aplasia, hooking clavicles, shortened ulna, and normal hands and humeri. (g, h) Subject 27
(with deletion of proximal and distal 1q21.1) at 17 months. Note brachycephaly, full cheeks, flat philtrum, and posteriorly rotated ears. (i) Subject 33
(with deletion of proximal and distal 1q21.1) at 8 months. Note radial hypoplasia. (j) Subject 40 (with proximal microduplication) at 4 months. Note square
forehead, prominence of the eyes, low nasal bridge, and flame nevus. (k) Subject 41 (with proximal microduplication) at 6 years. Note strabismus, broad
nasal bridge, prominent ears, and myopathic facies with open mouth. (l, m) Subject 47 (with proximal microduplication) at 8 years. Note epicanthal folds,
cleft lip repair, toenail dystrophy, and wide feet. (n) Subject 70 (with distal microdeletion) at 3.5 years. Note slight midfacial flattening and triangular nose.
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region in our cases did not show a significant difference in frequencies
compared with controls (26/45744 vs 2/11757; one-tailed P¼0.055,
Fisher’s exact test).
DISCUSSION
Individuals reported here with 1q21.1 microdeletions and micro-
duplications show variability in phenotypes. The features present in
a majority or near majority of individuals with microdeletions or
microduplications limited to proximal, BP2–BP3 1q21.1 were a
history of failure to thrive or feeding problems, DD/ID, dysmorphic
features, and behavior problems. Also, clinodactyly was common
among individuals with proximal microduplications (Tables 1
and 2). Some of these trends may reflect an ascertainment bias
based on common indications for study among individuals under-
going aCGH testing. To determine if these proximal microdeletions
and microduplications are benign or a susceptibility locus for the
development of an abnormal phenotype, we compared the frequencies
of the proximal microdeletion and microduplication in our patient
population with published control populations. Proximal BP2–BP3
microduplications were enriched among individuals referred for
aCGH testing, suggesting that this microduplication can contribute
to abnormal phenotypes in some carriers. Lack of enrichment for the
proximal BP2–BP3 microdeletion cannot support a similar conclusion
for the reciprocal microdeletion. This conclusion opposes that reached
in another recent study showing significant enrichment of proximal
1q21.1 microdeletions and lack of enrichment for the reciprocal
microduplication among a population of individuals undergoing
clinical aCGH testing.27 This is likely because of slight differences in
control frequencies for proximal microdeletions. Furthermore, prox-
imal microduplications had a significantly lower frequency in that
patient population than in ours; this may be because of underreport-
ing by some laboratories, which considered these microduplications to
be likely benign (Dr Christa Lese Martin, personal communication).
Given the rarity of the proximal microdeletions, larger control
populations may be required to reach definite conclusions about the
pathogenicity of these deletions. However, previous studies show this
microdeletion to be significantly enriched in cases of TAR syndrome,22
so this microdeletion at least contributes to the development of that
syndrome.
Subject 18, who has TAR syndrome, had an atypical, smaller
deletion within the BP2–BP3 1q21.1 segment, which may allow
refinement of a critical 1q21.1 region for the syndrome. Previously
proposed TAR candidate genes PIAS3, a regulator of hematopoietic
growth factor signaling, and LIX1L, which shares homology with a
gene involved in limb development,22 are at least partially within this
















Microcephaly 3/11 13/16 28/50





Hypotonia 1/12 2/22 11/59h
Seizures 4/12 2/23f 9/60g,h
Autistic features 4/13i 0/22 6/57f,h,j
Other behavioral problems 4/12 1/22 15/58h
Hearing loss 2/12 4/22 3/58
Brain abnormalities 4/9 2/4 6/11
Dysmorphic features 8/12 14/17 43/57




Craniosynostosis 0/12 1/22 1/58
Skeletal limb abnormalities 1/12 2/22 3/58
Polydactyly 0/12 1/22 8/58
Other skeletal anomalies 3/12 1/22 2/58
Ligamentous laxity 0/12 2/22 5/58
Cardiac anomalies 2/12 5/22 15/58
Lung abnormalities 0/12 2/22 0/58
Renal anomalies 1/12 5/22 4/58
Genital anomalies 1/12 3/22 1/58
Blood disorders 2/12 0/22 0/58
aSubjects 1–12 from this report, who do not meet clinical criteria for TAR syndrome.
bPreviously reported probands2,6,17,51 and subjects 23–34 from this report.
cPreviously reported probands2,3,5,6,18,19,52 and subjects 56–70 from this report.
dAlso includes a previously reported proband in a schizophrenia cohort.15
eAlso includes previously reported probands in a schizophrenia cohort.11
fAlso includes previously reported probands in a schizophrenia cohort.12
gAlso includes a previously reported proband in a schizophrenia cohort.10
hAlso includes a previously reported proband in an epilepsy cohort.53
iAlso includes a previously reported proband in an autism cohort.25
jAlso includes a previously reported proband in an autism cohort.8












Short stature 3/13 NS 2/21
Failure to thrive/feeding problems 5/10 NS 4/20
Microcephaly 2/12 NS 2/23




Hypotonia 5/16 0/2 4/27
Seizures 2/16 0/2 5/28
Autistic features 4/14 0/2 14/34d
Other behavioral problems 6/14 0/2 1/25
Hearing loss 1/16 0/2 0/27
Brain abnormalities 5/7 NS 3/4
Dysmorphic features 9/16 0/2 14/27
Cataracts 0/16 0/2 0/27
Other ophthalmologic abnormalities 5/16 0/2 4/27
Craniosynostosis 1/16 0/2 0/27
Skeletal limb abnormalities 4/17 0/2 0/27
Other skeletal anomalies 3/17 0/2 2/27
Clinodactyly 6/17 0/2 1/27
Ligamentous laxity 1/16 0/2 1/27
Cardiac anomalies 3/17 1/2 8/28e
Lung abnormalities 2/17 0/2 0/27
Renal anomalies 1/17 0/2 1/27
Genital anomalies 3/17 1/2 3/27
Blood disorders 0/16 0/2 0/27
Abbreviation: NS, not specified.
aPreviously reported proband24 and subjects 36–51 from this report.
bPreviously reported probands.17,54
cPreviously reported probands.2,6,17,21
dAlso includes previously reported probands in autism cohorts.7–9
eAlso includes previously reported probands.20
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subject’s deletion region (Figure 1). Of note, 3 subjects not meeting
the clinical criteria for TAR syndrome but with proximal 1q21.1
microdeletions presented with features related to the hallmark features
of the syndrome: subject 9 had radioulnar synostosis, subject 7 had a
history of autoimmune neutropenia, and subject 22, who also carried
a mosaic 1.4-Mb supernumerary ring chromosome 17, had chronic
thrombocytopenia. Also, subject 33, who had a larger BP1/2–BP4
microdeletion, had bilateral radial hypoplasia (Figure 2), and subject
25, who had a large deletion, had dysplasia of the radial head and
lateral humeral epicondyle. Other features occasionally associated with
TAR syndrome were also seen in our cohort, including cow milk
intolerance and/or feeding problems, spinal abnormalities, heart
defects, renal and genital anomalies, seizures, and hearing loss
(Table 3). Some differences between phenotypic incidences in TAR
syndrome and individuals with proximal microdeletions not meeting
TAR syndrome criteria, including dysmorphic features, ID/DD,
seizures, and behavioral problems, may reflect our ascertainment
bias of individuals undergoing genetic testing. Cardiac and renal
anomalies occurred in similar frequencies among all individuals
with proximal microdeletions, which may be more representative of
the incidence of these anomalies with this CNV. These results suggest
that TAR syndrome may be at the severe end of a spectrum of
phenotypic abnormalities caused by proximal 1q21.1 microdeletions,
and some individuals may only develop part of the syndrome’s
phenotype. This is consistent with the previously proposed model
for TAR syndrome, as genetic changes at one or more other,
unidentified modifier loci (mTAR) likely determine the ultimate
phenotypic expression in these individuals.22
Early reports on individuals with TAR syndrome noted a 7%
incidence of significant DD. The original presumptions were that
the delays were caused by micro-infarcts secondary to the thrombo-
cytopenia.35,36 Several lines of evidence, however, have suggested
otherwise. First, patients with other causes of thrombocytopenia did
not demonstrate the same level of delays. Second, MRI data has
suggested an etiology that is primarily dysgenesis, not injury.37 The
understanding of the nature of the 1q21.1 deletions now offers a better
explanation. Similar to individuals with TAR syndrome, the brain
anomalies in some individuals in this cohort with proximal 1q21.1
microdeletions, including corpus callosum thinning and cysts identi-
fied by MRI (Supplementary Table 2), were not suggestive of injury.
The proximal 1q21.1 region likely contains genes that, when deleted,
can contribute to TAR syndrome in addition to genes that impact
cerebral development, which would explain why some individuals
with TAR syndrome and some with proximal 1q21.1 microdeletions
not meeting clinical criteria for TAR syndrome show DD.
Table 3 Comparison of features in TAR syndrome and probands











Bilateral radial aplasia 99c,d 35/35 0/12




Ulnar abnormalities 74d 28/29 1/12
Humerus abnormalities 41d 19/29 0/12
Hand abnormalities 85d 24/28 1/12
Lower limb abnormalities 46c,d 17/28 0/12
Foot abnormalities 40e 6/28 0/12
Spine/rib abnormalities 7c,e 1/28 3/12
Cardiac anomalies 19c,d 5/27 2/12
Renal anomalies 23c 4/26 1/12
Uterine or genital anomalies 5c,e 4/26 1/12
Cleft palate 1c,d 2/27 0/12
Micrognathia 14d 1/2 1/12
Hemangioma 24c 2/26 0/12




Behavior problems NA 0/2 7/13f
Seizures 6c 2/26 4/12
Brain abnormalities NA 1/3 4/9
Hearing loss 3c 2/26 2/12
Ophthalmologic abnormalities NA 0/2 4/12
Abbreviation: NA, not available.
aPreviously reported probands with TAR syndrome and deletions limited to the proximal region
of 1q21.1,22,23,56 and subjects 13–18 in this report, who had clinical diagnoses or prenatally
suspected diagnosis of TAR syndrome.
bSubjects 1–12 from this report, who do not meet clinical criteria for TAR syndrome.
cBased on review by Hedberg et al.36
dBased on cohort published by Greenhalgh et al.55
eBased on review by Hall et al.35
fAlso includes individual reported by Shen et al.25







Del 1q21.1Del 1q21.1Del 1q21.1Del 1q21.1Del 1q21.1
Del 1q21.1 No del 1q21.1No del 1q21.1No del 1q21.1 Not tested
Subject 3 Subject 5 Subject 8
Not tested
Not tested
Del 1q21.1 Del 1q21.1Del 1q21.1
Del 1q21.1
No del 1q21.1 No del 1q21.1









Figure 3 Pedigrees of families with individuals carrying the proximal, BP2–BP3 1q21.1 microdeletion. Individuals shown to have ‘other neurological
features’ had seizures, behavioral abnormalities, abnormal head size, and/or other brain abnormalities detected by imaging. LD, learning disability.
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Like the individuals with the proximal microdeletions, individuals
with the reciprocal BP2–BP3 microduplication had variable pheno-
typic features, with the most common features – ID/DD, dysmorphic
features, and behavioral problems (Table 2) – possibly because of an
ascertainment bias. Additionally, individuals in our cohort had other
environmental and genetic factors that could contribute to the
abnormal phenotypes, including documented prenatal exposures,
poor social situations, and consanguinity. Despite the presence of
these complicating factors, enrichment of the microduplication in our
patient population suggests that the proximal, BP2–BP3 1q21.1
microduplication has a causative role in abnormal phenotypes.
Some rarer, specific phenotypes were seen in several individuals
with 1q21.1 abnormalities. These may represent a rare causative
association with these features, or the association may be owing to
chance. Congenital cystic adenomatoid malformation (CCAM) type II
of the lung has been reported in two individuals with large, BP1/2-BP4
deletions (subject 32 here and patient 17 in Brunetti-Pierri et al 4). As
CCAM is likely because of the focal arrest in lung maturation during
the fetal period,38 candidate genes for this malformation include genes
with roles in developmental pathways, including PIAS3 and RBM8A,
which regulate STAT3,39,40 involved in lung branching morphogen-
esis;41 BCL9, which is involved in the b-catenin/WNT pathway,42 also
active in the lung development;43 and PEX11B, which encodes a
peroxisome biogenesis factor hypothesized to be important in devel-
oping airways and during alveolarization.44 There have been multiple
reports of polydactyly associated with the distal, BP3–BP4 microdele-
tion (Table 1). A candidate gene for this malformation is BCL9
(homolog of Drosophila gene legless), which is essential in vertebrate
body axis determination.45 Finally, it has been hypothesized that the
head size variation observed with distal 1q21.1 rearrangements is
associated with copy number changes of genes within the SDs in the
region, either the HYDIN paralog within BP36 or the NPBF family
genes within all of the BPs (Figure 1).46 If micro- and macrocephaly
are associated with copy number alteration of genes within the SDs,
then proximal rearrangements could also alter the copy number of
these genes. However, head sizes are not significantly different between
individuals with microdeletions and microduplications limited to
BP2–BP3 (P¼0.85, unpaired t-test; mean z-score 0.64 and 95%
confidence interval 2.72 to 1.43 for microdeletions, and mean
z-score 0.45 and 95% confidence interval 1.74 to 0.84 for micro-
duplications; Tables 1 and 2; Supplementary Table 2). This lack of
consistent head size abnormalities with proximal CNVs could be
attributed to the involvement of different genes within the SDs in
proximal and distal rearrangements, or additional genes within the
BP3–BP4 region may contribute to alterations in head size. However,
our sample sizes are still small and many factors, including parental
head size, contribute to patient head size, so data from more
individuals and fine mapping of the common BPs within the SDs
will help clarify these conclusions.
Despite the lack of enrichment for the proximal microdeletions in
our patient population, some evidence is present for increased
selective pressure against the proximal microdeletion compared with
the reciprocal microduplication. In our patient population, de novo
microdeletions have been observed, whereas de novo microduplica-
tions have not (Table 4); this indicates a greater proportion of parents
with the microduplications are fit enough to reproduce. Also, prox-
imal microdeletions are significantly less frequent than the reciprocal
microduplications in our population of individuals undergoing aCGH
testing (two-tailed P¼3.6106, Fisher’s exact test) and control
populations (two-tailed P¼0.034, Fisher’s exact test), which may
indicate increased selective pressure against the proximal microdele-
tions, especially given that it has been predicted that, absent selection
or other factors, NAHR-mediated deletions should be more common
than duplications.47 This is similar to the effect seen to a greater extent
with small, reciprocal, NAHR-mediated CHRNA7 deletions and
duplications in 15q13.3; presumably benign duplications are much
more common than the harmful deletions (55/8800 vs 3/8800 in one
population).48,49 Although the relative frequencies of proximal 1q21.1
microdeletions and microduplications fit a pattern associated with
more significant phenotypic consequences with microdeletions, we
have also established that proximal 1q21.1 microduplications con-
tribute to abnormal phenotypes. The reason that there is increased
selective pressure against the microdeletion may be solely because of
selection against microdeletion carriers with TAR syndrome.
We show that the recurrent microdeletion of the proximal 1q21.1
region, which had previously only been significantly associated with
TAR syndrome,22 may also cause a partial TAR syndrome phenotype
in some carriers. The reciprocal duplications are enriched in our
patient population undergoing clinical aCGH testing, which indicates
that these duplications can also contribute to abnormal phenotypes.
Clinically normal individuals may also carry these 1q21.1 rearrange-
ments; abnormal phenotypes segregate with the microdeletion in
some but not all families, and the same CNV may contribute to
different phenotypes within the same family (Figure 3). Because of the
phenotypic variability and lack of consistent dysmorphic features,
with the exception of individuals with TAR syndrome, proximal
1q21.1 microdeletions and microduplications are unlikely to be
recognized clinically and diagnosis will likely continue to follow
molecular cytogenetic testing. Similar to what is observed with TAR
syndrome, these proximal 1q21.1 microdeletions and microduplica-
tions are likely one factor in the development of abnormal pheno-
types, and additional unidentified factors, both genetic and
environmental, will determine what, if any, phenotypic manifestations
will be present in an individual.50
Table 4 Inheritance of 1q21.1 abnormalities detected by Signature Genomics
BP2–BP3 deletions BP2–BP4 deletions BP3–BP4 deletions BP2–BP3 duplications BP2–BP4 duplications BP3–BP4 duplications
Frequency (%) 26/45744 (0.057)a,b 11/45744 (0.024) 86/30215 (0.28)c 72/45744 (0.16)d,e 12/45744 (0.026)d 57/30215 (0.19)b
de novo 5 2 6 0 2 6
Maternally inherited 9 0 15 6 1 17
Paternally inherited 5 1 12 6 1 8
Unknown (parents not tested) 7 8 53 60 8 26
aFive of these individuals had clinical diagnoses of TAR syndrome or demonstrated the skeletal manifestations of TAR syndrome prenatally.
bIncludes one individual with a complex, proximal deletion/distal duplication.
cIncludes two individuals with a complex, proximal duplication/distal deletion.
dTwo individuals with proximal duplications and unknown involvement of the distal region are not included in either group.
eIncludes six individuals with a complex, proximal duplication/distal deletion, and two individuals with a proximal duplication and a duplication of a distal portion of the BP3–BP4 region.
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